Fig. 5: LncRNA SNHG17 epigenetically inhibited LATS2 expression in PC9/GR and A549/GR cells. | Cell Death & Disease

Fig. 5: LncRNA SNHG17 epigenetically inhibited LATS2 expression in PC9/GR and A549/GR cells.

From: m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression

Fig. 5

A, B Distribution of lncRNA SNHG17 in the nucleus and cytoplasm in PC9/GR cells. C RIP-qPCR analysis was adopted to verify the interaction between lncRNA SNHG17 and EZH2 or LSD1. D Relative mRNA levels of p27, HMGA2, LATS2, KLF2 and TIMP2 were assessed by qRT-PCR in sh-NC, sh-SNHG17#1 and sh-SNHG17#2 transfected PC9/GR and A549/GR cells. E ChIP-qPCR was used to estimate the influences of sh-NC, sh-SNHG17#1 and sh-SNHG17#2 transfections on the binding levels of EZH2 and H3K27me3 on the LATS2 promoter. F, G Relative mRNA and protein expression of LATS2 was detected in EZH2- and lncRNA SNHG17-silenced PC9/GR and A549/GR cells. Data were representative images or were expressed as the mean ± SD of n = 3 experiments. *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page